As of 2026-09-14, the Relative Valuation of Kinnate Biopharma Inc (KNTE) is (63.76) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Kinnate Biopharma Inc based on Relative Valuation is -2506.2%.
The range of the Relative Valuation is (55.88) - (70.93) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 23.3x - 29.7x | 26.5x |
| Forward P/E multiples | 23.4x - 30.4x | 26.9x |
| Fair Price | (55.88) - (70.93) | (63.76) |
| Upside | -2208.8% - -2776.5% | -2506.2% |
| Date | P/E |